Deok Kim - Sinil Pharmaceutical Non-Executive Independent Director
| 012790 Stock | KRW 6,620 20.00 0.30% |
Director
Kim Deok Bong was NonExecutive Independent Director of SHINIL PHARMACEUTICAL CO., LTD since March 20, 2009. Kim is also President of a Koreabased company. Kim completed a Master Course in Business Administration from Kyungwon University, Korea. since 2009.
| Age | 66 |
| Tenure | 15 years |
| Phone | (82) 43 855 3944 |
| Web | www.sinilpharm.com |
Sinil Pharmaceutical Management Efficiency
The company has return on total asset (ROA) of 0.0247 % which means that it generated a profit of $0.0247 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 9.5865 %, meaning that it generated $9.5865 on every $100 dollars invested by stockholders. Sinil Pharmaceutical's management efficiency ratios could be used to measure how well Sinil Pharmaceutical manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 7 records | DIRECTOR Age | ||
| JongTae Jung | Bohae Brewery | 72 | |
| JaeTaek Yoo | Lotte Data Communication | 62 | |
| JoonHyung Noh | Lotte Data Communication | 55 | |
| BoYoung Oh | Lotte Data Communication | 61 | |
| JongMin Yoon | Lotte Data Communication | 63 | |
| Jeong Ha | Youngsin Metal Industrial | 50 | |
| JunSung Kim | Bohae Brewery | 66 | |
Management Performance
| Return On Equity | 9.59 | |||
| Return On Asset | 0.0247 |
Sinil Pharmaceutical Leadership Team
Elected by the shareholders, the Sinil Pharmaceutical's board of directors comprises two types of representatives: Sinil Pharmaceutical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Sinil. The board's role is to monitor Sinil Pharmaceutical's management team and ensure that shareholders' interests are well served. Sinil Pharmaceutical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Sinil Pharmaceutical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jae Hong, Chief Executive Officer, Director | ||
| JaeHyun Hong, Managing Director | ||
| JongChang Park, Managing Director | ||
| MiKeun Jung, Chief Pres | ||
| Hyeon Hong, Director | ||
| Jeong Lee, Assistant Managing Director | ||
| Se Choi, Internal Auditor | ||
| Seong Hong, Chairman of the Board | ||
| JungMin Lee, Managing Center | ||
| Deok Kim, Non-Executive Independent Director | ||
| YoungShin Ok, Managing Director | ||
| Jong Park, Assistant Managing Director |
Sinil Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Sinil Pharmaceutical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 9.59 | |||
| Return On Asset | 0.0247 | |||
| Profit Margin | 0.09 % | |||
| Operating Margin | 0.08 % | |||
| Current Valuation | 159.61 B | |||
| Shares Outstanding | 7.5 M | |||
| Shares Owned By Insiders | 40.12 % | |||
| Shares Owned By Institutions | 0.58 % | |||
| Price To Earning | 15.03 X | |||
| Price To Sales | 1.00 X |
Pair Trading with Sinil Pharmaceutical
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Sinil Pharmaceutical position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Sinil Pharmaceutical will appreciate offsetting losses from the drop in the long position's value.Moving together with Sinil Stock
The ability to find closely correlated positions to Sinil Pharmaceutical could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Sinil Pharmaceutical when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Sinil Pharmaceutical - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Sinil Pharmaceutical Co to buy it.
The correlation of Sinil Pharmaceutical is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Sinil Pharmaceutical moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Sinil Pharmaceutical moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Sinil Pharmaceutical can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in Sinil Stock
Sinil Pharmaceutical financial ratios help investors to determine whether Sinil Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Sinil with respect to the benefits of owning Sinil Pharmaceutical security.